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Targeting Vascular Endothelial Growth Factor in Lung
Cancer
Arman Hasani, MBBS, FRACP,* and Natasha B. Leighl, MD, MMSc, FRCPC†
Vascular endothelial growth factor (VEGF), as a key me-diator of angiogenesis and important prognostic factor in
lung cancer, remains a major target in drug development for
this disease. Recent developments and future directions were
discussed at the 10th Annual Targeted Therapies of the
Treatment of Lung Cancer in Santa Monica.
SUMMARY OF PRESENTATIONS
Agents Targeting VEGF Ligand
Dr. Zhang (University of Southern California) pre-
sented an exploratory subset analysis of E4599, examining
germline polymorphisms of angiogenic factors as potential
predictive biomarkers for benefit from bevacizumab. Of 879
patients enrolled on E4599, samples from 133 were available,
of whom 66 received bevacizumab. A profile of three single
nucleotide polymorphisms in IL-8, VEGF, and ICAM-1 was
generated from patients responding to bevacizumab-based
therapy. This profile was associated with better progression-
free survival (PFS; hazard ratio [HR]: 0.40; median: 9.2
versus 5.4 months; p  0.002) and overall survival (OS; HR:
0.39; median: 16.8 versus 10.2 months; p  0.0001). Inter-
estingly, this profile was not prognostic in the cohort of
chemotherapy-treated controls and will hopefully be vali-
dated in further studies.
Professor Scagliotti (University of Torino) reviewed
the development of aflibercept (VEGF Trap), a recombinant
fusion protein that binds VEGF-A, VEGF-B, and placental
growth factor. As a single agent, aflibercept achieved a high
rate of stable disease (68.4%) but only 2% response rate (RR)
in patients with platinum and erlotinib-resistant nonsquamous
non-small cell lung cancer (NSCLC).1 A large phase III study
of second-line docetaxel plus aflibercept/placebo has com-
pleted accrual, and a phase II study of first-line pemetrexed/
cisplatin/aflibercept is ongoing.
Monoclonal Antibody Targeting Vascular
Endothelial Growth Factor Receptor-2
Dr. Doebele (University of Colorado) outlined the de-
velopment of ramucirumab (IMC-1121B), a fully human
anti-vascular endothelial growth factor receptor (VEGFR)-2
IgG1 monoclonal antibody. Phase II studies are underway or
planned, combining ramucirumab with first-line chemother-
apy. One trial focuses on patients with squamous histology,
using gemcitabine/carboplatin  ramucirumab; another will
enrol patients with nonsquamous histology, to receive pem-
etrexed/carboplatin  ramucirumab.
Oral Small-Molecule Tyrosine Kinase Inhibitors
The development of pazopanib (targets VEGFR, plate-
let derived growth factor receptor, and c-kit) in NSCLC was
summarized by Prof. Scagliotti. A single-arm phase II study
of preoperative pazopanib (median 16 days treatment) in 35
patients with early-stage NSCLC demonstrated tumor shrink-
age in 86% and a RR of 8.6%. Baseline plasma levels of
IL-12 and hepatocyte growth factor were associated with
response (accuracy 81%), whereas changes in plasma IL-12,
hepatocyte growth factor, and VEGFR2 were associated with
reduction in tumor volume. Pazopanib plus pemetrexed dem-
onstrated a 15% RR in 15 patients with NSCLC. Pazopanib
plus erlotinib in 33 patients (13 with NSCLC) reported three
responses, all in patients with NSCLC. Pazopanib plus car-
boplatin/paclitaxel in phase I demonstrated significantly in-
creased exposure to paclitaxel and carboplatin, resulting in
hematologic toxicity.
Dr. Heymach (MD Anderson) reviewed NSCLC treat-
ment with sorafenib (targets RAF, VEGFR-2, and platelet
derived growth factor receptor). Sorafenib has demonstrated
single-agent efficacy in NSCLC. Nevertheless, the phase III
ESCAPE trial indicated that adding sorafenib to first-line
carboplatin/paclitaxel for advanced NSCLC did not improve
OS, and survival was inferior for patients with squamous cell
carcinoma who received sorafenib.2 This study was termi-
nated early, and the NExUS trial (cisplatin/gemcitabine with
sorafenib/placebo) was amended to exclude patients with
squamous histology.
Dr. Schiller (University of Texas Southwestern) dis-
cussed axitinib in NSCLC (targets VEGFR-1, -2, and -3). A
randomized phase II study in nonsquamous chemonaive pa-
tients of axitinib/paclitaxel/carboplatin versus bevacizumab/
paclitaxel/carboplatin, followed by maintenance axitinib or
bevacizumab is ongoing. A phase III study of pemetrexed/
cisplatin  axitinib in patients with nonsquamous NSCLC
has completed recruitment, and results are pending. A single-
arm study of gemcitabine/cisplatin and axitinib in patients
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with squamous NSCLC has also completed accrual. The
development of hypertension has been identified as a poten-
tial predictor of better OS from six trials of axitinib in
multiple tumor types including NSCLC.3
Ongoing studies of sunitinib in NSCLC were also
outlined by Dr. Schiller. These include a randomized phase II
study of erlotinib  sunitinib second line and a trial of
maintenance therapy, sunitinib versus placebo, in patients
who have not progressed on first-line platinum-based chemo-
therapy. Sunitinib is being combined with etoposide/cisplatin
in extensive stage SCLC in the CALGB 30504 study (phase IB).
Dr. Wakelee (Stanford) reviewed XL647 studies in
NSCLC (targets EGFR, HER2, and VEGFR-2). A phase II
trial of XL647 in 38 selected chemotherapy-naive patients
with advanced NSCLC reported a 26% RR; three responders
had wild-type EGFR in their tumors.4 Another study in 39
EGFR tyrosine kinase inhibitor (TKI)-resistant patients, one
response and stable disease in 49% were seen. Nevertheless,
plans for future studies are unclear.
BIBF-1120 targets VEGFR, platelet derived growth
factor receptor, FGFR and some SRC kinases. Dr. Wakelee
summarized a phase II study of second- or third-line BIBF-
1120 treatment of 73 patients with advanced NSCLC that
demonstrated one response and a stable disease rate of 48%.5
Phase I studies did not show pharmacokinetic interactions
with pemetrexed or combination carboplatin/paclitaxel.6,7
Phase II and III trials of these combinations in all NSCLC
histologies are planned or ongoing.
Dr. Herbst (MD Anderson) discussed the accumulating
evidence for dual inhibition of the EGFR and VEGF path-
ways. The BETA-Lung and ATLAS studies have shown that
combination bevacizumab and erlotinib result in a modest
improvement in PFS compared with either alone but without
improving OS.8 Vandetanib targets VEGFR-2, -3, and EGFR
and has been studied in multiple NSCLC trials. ZODIAC
randomized patients to second-line docetaxel plus vandetanib
or placebo.9 PFS (4 versus 3.2 months, HR, 0.722, p 
0.0012) and time to symptom deterioration were superior in
the vandetanib arm, but there was no difference in OS. ZEAL
tested pemetrexed  vandetanib and showed a similar trend
but was not significant for PFS benefit.10 Vandetanib and
erlotinib were compared in the ZEST trial and had similar
PFS and OS.11 ZEPHYR, a placebo-controlled randomized
study of vandetanib after chemotherapy and EGFR TKI
failure, has reported no improvement in survival, with data to
be presented later this year.
Dr. Goss (University of Ottawa) reviewed tivozanib, a
potent VEGFR inhibitor, which seems well tolerated and
achieved a high rate of disease control (84%) in patients with
renal cancer12 and is in early phase studies in NSCLC.
Studies of cediranib in NSCLC, another potent VEGFR
inhibitor, were presented by Dr. Goss. Results of a phase I
trial of cediranib plus cisplatin/etoposide in SCLC and neu-
roendocrine tumors are expected later this year, as are results
from a randomized phase II study of first-line gemcitabine/
carboplatin  cediranib in advanced disease. Cediranib is
also being combined with pemetrexed second line, and in 33
patients accrued, has shown a disease control rate of 71% and
RR of 16%.13 The National Cancer Institute of Canada
Clinical Trials Group BR.24 randomized phase II trial of
paclitaxel/carboplatin plus cediranib/placebo demonstrated
higher RRs (38% versus 16%) and a trend to better PFS (HR:
0.77, 95% CI: 0.56–1.08). For toxicity reasons, the subse-
quent National Cancer Institute of Canada CTG BR.29 phase
II/III trial of paclitaxel/carboplatin  cediranib will use a
lower dose of cediranib, 20 mg daily reduced from 30/45 mg
studied previously. In mesothelioma, SWOG 0507 demon-
strated a disease control rate of 42% and median PFS of
approximately 3 months with cediranib.14 A phase I/II study
is planned by SWOG of combination cediranib with pem-
etrexed/cisplatin in mesothelioma.
CONCLUSIONS AND FUTURE DIRECTIONS
Although bevacizumab has been incorporated into stan-
dard therapy,15 particularly in the United States for eligible
patients, several other VEGF inhibitors also demonstrate
activity and are under development. Given the evolution of
patient selection based on histology and genotype for differ-
ent treatment options, future research will need to focus on
the role of biomarkers to identify those patients who derive
preferential benefit from VEGF inhibition.
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